Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Silexion Therapeutics completed a 1-for-10 reverse share split effective May 28, 2026, to maintain Nasdaq listing compliance and support its clinical development of SIL-204 for KRAS-driven cancers. The move aims to achieve a higher stock price, reduce volatility, and broaden investor access ahead of Phase 2/3 trial initiation.